Patent · US Expired

Use of docetaxel for treating cancers

US6333348A · kind A · utility

59Cited by
0References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 6, 2000
Grant dateDec 25, 2001
Priority date
Expiry dateApr 6, 2020

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to a method of treating cancer, comprising administering a dose of docetaxel and a dose of rhuMAb HER2 to a patient in need thereof, wherein said dosages have a synergistic therapeutic effect when compared to the administration of docetaxel or rhuMAb HER2 alone.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.